Skip to main content

Advertisement

Table 1 Association of the expression of MIF, CXCR4 and clinicopathologic parameters in 136 patients with ESCC

From: The expressions of MIF and CXCR4 protein in tumor microenvironment are adverse prognostic factors in patients with esophageal squamous cell carcinoma

Clinicopathologic parameter Case Expression in tumor cells Expression in TILs
   High level expression of MIF (%) P a High level expression of CXCR4 (%) P a High level expression of MIF (%) P a High level expression of CXCR4 (%) P a
Age          
≤62 (y) 71 35 (49.3%) 0.284 26 (36.6%) 0.597 31 (43.7%) 0.122 38 (53.5%) 0.391
>62 (y) 65 38 (58.5%)   21 (32.3%)   37 (56.9%)   30 (46.2%)  
Gender          
Female 25 11 (44.0%) 0.283 9 (36.0%) 0.867 14 (56.0%) 0.507 17 (68.0%) 0.075b
Male 111 62 (55.9%)   38 (34.2%)   54 (48.6%)   51 (45.9%)  
WHO grade          
G1 40 27 (67.5%) 0.087 13 (32.5%) 0.669 22 (55.0%) 0.579 19 (47.5%) 0.448
G2 59 30 (50.8%)   19 (32.2%)   30 (50.8%)   33 (55.9%)  
G3 37 16 (43.2%)   15 (40.5%)   16 (43.2%)   16 (43.2%)  
T status          
T1-2 44 22 (50.0%) 0.552 10 (22.7%) 0.045* 19 (43.2%) 0.271 24 (54.5%) 0.463
T3-4 92 51 (55.4%)   37 (40.2%)   49 (53.3%)   44 (47.8%)  
N status          
N0 69 36 (52.2%) 0.721 20 (29.0%) 0.165 32 (46.4%) 0.391 37 (53.6%) 0.391
N1 67 37 (55.2%)   27 (40.3%)   36 (53.7%)   31 (46.3%)  
Clinical stage          
I-II 74 41 (55.4%) 0.659 20 (27.0%) 0.044* 37 (50.0%) 1.00 41 (55.4%) 0.168
III-IV 62 32 (51.6%)   27 (43.5%)   31 (50.0%)   27 (43.5%)  
  1. Note: *P < 0.05, a, Pearson’s X2 test. b, Fisher’s X2 test.